This course is meant to enhance the quality of benchmarking outputs by providing the basis of harmonizing approaches among assessors using the GBT (Global Benchmarking Tool) to benchmark regulatory authorities.

Visceral leishmaniasis (VL), also known as kala-azar, is fatal if left untreated in over 95% of cases. It is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anaemia. East Africa is currently reporting the highest number of VL cases worldwide. 

The course will provide you with the basic knowledge to understand key components and functionality of the WHO costing and budgeting tool for national action plans on AMR.

The aim of this course is to provide information on the “WHO implementation handbook for national action plans on antimicrobial resistance: guidance for the human health sector” and the 6 steps for sustainable implementation of NAPs on AMR.

The aim of this course is to provide guidance for countries on the monitoring and evaluation of national action plans on antimicrobial resistance (AMR NAPs).

Onchocerciasis – or “river blindness” – is a parasitic disease caused by the filarial worm Onchocerca volvulus transmitted by repeated bites of infected blackflies (Simulium spp.). These blackflies breed along fast-flowing rivers and streams, close to remote villages located near fertile land where people rely on agriculture.

Superficial fungal infections are some of the most prevalent diseases across the world. This course explores the epidemiology, clinical presentation, diagnosis, and management of the most common superficial fungal infections globally. This course also talks about the rapid spread of drug-resistant dermatophytes and how to mitigate its effects.

Buruli ulcer is a chronic debilitating disease Mycobacterium ulcerans that mainly affects the skin and sometimes bone. The mode of transmission to humans is unknown. Currently, early diagnosis and treatment are crucial to minimizing morbidity, costs and prevent long-term disability.

El objetivo de este curso es presentar las Buenas prácticas de confianza regulatoria de la OMS y promover el uso de enfoques basados en la confianza regulatoria en la supervisión regulatoria de los productos médicos. Este curso está dirigido al personal de las autoridades reguladoras nacionales y a todas las partes interesadas en los enfoques basados en la confianza regulatoria.